# Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia

> **NCT04241705** · NA · UNKNOWN · sponsor: **Armauer Hansen Research Institute, Ethiopia** · enrollment: 48960 (estimated)

## Conditions studied

- Malaria

## Interventions

- **OTHER:** Treatment of positive individuals per national treatment guidelines
- **OTHER:** Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)
- **OTHER:** Optimized malaria control interventions

## Key facts

- **NCT ID:** NCT04241705
- **Lead sponsor:** Armauer Hansen Research Institute, Ethiopia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-20
- **Primary completion:** 2022-01-20
- **Final completion:** 2022-01-20
- **Target enrollment:** 48960 (ESTIMATED)
- **Last updated:** 2020-06-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04241705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04241705, "Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04241705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*